Previously, our Chief Operating Officer Sultan Beardsley outlined an investment thesis for RegenXBio. This detailed report can be read here: Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It. This week, we will get more color on potential revenue for RegenXBio. Today, I will provide a brief financial update on its first commercial product, Zolgensma, which was licensed to AxeXis prior to their buyout by Novartis. I will also discuss what to watch for this week and what to expect . . .
About Chris Stang
As a young investor, I focus developing biotech companies. I focus strongly on fundamentals, digging deeper to understand the financial and regulatory position of companies. The biotechnology sector is very volatile, please use caution and do your own additional due diligence before investing. I also secondarily focus on small security and defense companies that provide long-term growth opportunities.